3SBio Inc. to Report 2009 Third Quarter Earnings on November 12, 2009
SHENYANG, China, Oct. 28 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for t...
3SBio Inc. Announces Results of Annual General Meeting
SHENYANG, China, Oct. 20 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the results of its annual general meeting of sha...
3SBio Inc. to Hold 2009 Annual General Meeting on October 12, 2009
SHENYANG, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) (“3SBio” or “Company”), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that the annual general meeting of sha...
3SBio Inc. Announces Unaudited Second Quarter 2009 Results
Second quarter revenue grew 36.8% year-over-year to RMB81.5 million (US$11.9million) Operating income grew 69.9% year-over-year to RMB25.8 million (US$3.8 million) Company reiterates FY2009 revenue guidance SHENYANG, China, Aug. 12 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBi...
3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009
SHENYANG, China, July 23 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for the second quarter...
3SBio Inc. Announces Unaudited First Quarter 2009 Results
First Quarter Revenue Grows 23.7% Year-over-year to RMB68.6 Million (US$10.0 Million); Operating Income Grows 41.7% Year-over-year to RMB20.1 million (US$2.9 million); Company Reiterates FY2009 Revenue Guidance SHENYANG, China, May 20 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or...
3SBio Inc. Announces Appointment of Ernst & Young Hua Ming as Independent Auditor
SHENYANG, China, May 5 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced the appointment of Ernst & Young Hua Ming ("Er...
3SBio Inc. to Report 2009 First Quarter Earnings on May 19, 2009
SHENYANG, China, May 4 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for the first quarter ended March ...
3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results
Company Exceeds Guidance with 2008 Revenue of RMB243.2 million (US$35.7 million); Full year 2008 Adjusted Non-GAAP Operating Income Grew 20.6% over 2007 to RMB59.7 million (US$8.8 million) Provides 2009 Net Revenue Guidance Range of US$43-US$45 million SHENYANG, China, March 12 /PRNews...
3SBio Inc. Receives Official Recognition as a ‘High-Tech Enterprise’
SHENYANG, China, March 5 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that, in accordance with the relevant provisions issued by the Office o...
3SBio Inc. to Report 2008 Fourth Quarter and Full Year Earnings on March 11, 2009
SHENYANG, China, Feb. 25 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release financial results for the fourth quarter and full ...
3SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer
SHENYANG, China, Feb. 9 /PRNewswire-Asia/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has appointed Mr. Bo Tan as Chief Financial Officer, ef...
3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP
SHENYANG, China, Jan. 20 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it filed on December 30, 2008 with the Chinese St...
3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference
SHENYANG, China, Nov. 25 /PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announced that Dr. Yingfei Wei, Chief Scientific Officer, will present at the Piper J...
3SBio Inc. Announces Third Quarter 2008 Results
SHENYANG, China, Nov. 11 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or the "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the th...
3SBio Inc. Files for SFDA Approval of NuLeusin
SHENYANG, China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and Drug Adminis...
3SBio Inc. Announces Preliminary Third Quarter 2008 Results
-- Expects One-Time Impairment Charge of RMB19.0 million (US$2.7 million) -- Affirms 2008 Full Year Guidance SHENYANG, China, Nov. 1 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading biotechnology company focused on researching, d...
3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
Earnings Conference Call to be Held on November 11, 2008 at 5:00 am (Pacific) / 8:00 am (Eastern) / 9:00 pm (Beijing/Hong Kong) SHENYANG, China, Oct. 16 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading China-based biotechnology company focused on researching, developing, ...
3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
SHENYANG, China, Sept. 25 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and D...
3SBio Inc. to Present at the UBS Global Life Sciences Conference
SHENYANG, China, Sept. 17 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, announced that David Chen, Chief Operating Officer, will present at the UBS G...
